DK2968529T3 - Fremstilling af jordnøddeformuleringer til oral desensibilisering - Google Patents

Fremstilling af jordnøddeformuleringer til oral desensibilisering Download PDF

Info

Publication number
DK2968529T3
DK2968529T3 DK14776121.7T DK14776121T DK2968529T3 DK 2968529 T3 DK2968529 T3 DK 2968529T3 DK 14776121 T DK14776121 T DK 14776121T DK 2968529 T3 DK2968529 T3 DK 2968529T3
Authority
DK
Denmark
Prior art keywords
peanuty
desensibilization
formulations
oral
preparation
Prior art date
Application number
DK14776121.7T
Other languages
English (en)
Inventor
Bryan Walser
Howard V Raff
Original Assignee
Aimmune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2968529(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aimmune Therapeutics Inc filed Critical Aimmune Therapeutics Inc
Application granted granted Critical
Publication of DK2968529T3 publication Critical patent/DK2968529T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4875Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK14776121.7T 2013-03-14 2014-03-12 Fremstilling af jordnøddeformuleringer til oral desensibilisering DK2968529T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784964P 2013-03-14 2013-03-14
PCT/US2014/024401 WO2014159607A1 (en) 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization

Publications (1)

Publication Number Publication Date
DK2968529T3 true DK2968529T3 (da) 2020-10-12

Family

ID=51528061

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14776121.7T DK2968529T3 (da) 2013-03-14 2014-03-12 Fremstilling af jordnøddeformuleringer til oral desensibilisering
DK18213124.3T DK3482771T3 (da) 2013-03-14 2014-03-12 Fremstilling af jordnøddeformuleringer til oral desensibilisering

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18213124.3T DK3482771T3 (da) 2013-03-14 2014-03-12 Fremstilling af jordnøddeformuleringer til oral desensibilisering

Country Status (18)

Country Link
US (5) US9198869B2 (da)
EP (3) EP3482771B1 (da)
JP (3) JP6752140B2 (da)
CN (2) CN105101994B (da)
AU (5) AU2014240404B2 (da)
BR (1) BR112015021756B1 (da)
CA (1) CA2903229A1 (da)
DK (2) DK2968529T3 (da)
ES (2) ES2826224T3 (da)
FI (2) FI3482771T3 (da)
FR (1) FR23C1026I1 (da)
HK (1) HK1217660A1 (da)
HU (1) HUE051831T2 (da)
MX (1) MX2015010315A (da)
PL (1) PL2968529T3 (da)
PT (1) PT2968529T (da)
SI (1) SI2968529T1 (da)
WO (1) WO2014159607A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
EP3482771B1 (en) * 2013-03-14 2023-01-18 Société des Produits Nestlé S.A. Manufacture of peanut formulations for oral desensitization
WO2016033094A1 (en) 2014-08-25 2016-03-03 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
PL3258962T3 (pl) 2015-02-20 2023-04-24 The Board Of Trustees Of The Leland Stanford Junior University Mieszane kompozycje alergenów i sposoby ich stosowania
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
TW201709926A (zh) * 2015-04-23 2017-03-16 賽諾菲公司 用於舌下投藥之吡喃葡萄糖基脂a及過敏原調配物
US10856567B2 (en) 2016-07-22 2020-12-08 Kari Brown Baby food products containing allergenic proteins and methods of delivering same
AU2016431600B2 (en) * 2016-12-05 2024-05-23 Reacta Biotech Limited Oral food challenge meal formulations
SG10201913846XA (en) * 2017-01-13 2020-03-30 Aimmune Therapeutics Inc Methods of manufacture of nut flours and formulations for oral immunotherapy
BR102017026619A2 (pt) 2017-02-15 2018-10-30 Euroimmun Medizinische Labordiagnostika Ag ensaio melhorado para a diagnose de alergia a amendoim
SG11202000419QA (en) 2017-07-18 2020-02-27 Before Brands Inc Methods for making mixed allergen compositions
MX2020004683A (es) 2017-11-02 2020-08-13 Aimmune Therapeutics Inc Metodos de inmunoterapia oral.
GB201718342D0 (en) * 2017-11-06 2017-12-20 Cambridge Allergy Ltd Allergenic protein formulations for immunotherapy
CN112638413A (zh) 2018-07-27 2021-04-09 艾慕恩治疗公司 口服免疫治疗单位剂量分配系统和方法
CA3122854A1 (en) * 2018-12-17 2020-06-25 Aimmune Therapeutics, Inc. Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
EP3897681A4 (en) * 2018-12-20 2022-10-26 Société des Produits Nestlé S.A. DOSING SCHEDULE APPLICABLE FOR ORAL IMMUNOTHERAPY AGAINST PEANUT FOR MISSED DOSES
EP3914098A1 (en) 2019-01-23 2021-12-01 Before Brands, Inc. Methods for making mixed allergen compositions
CN113966229A (zh) 2019-05-10 2022-01-21 爱沐疗法公司 用于改善花生过敏患者的生活质量的方法
KR20220044543A (ko) * 2019-08-08 2022-04-08 에보니크 오퍼레이션즈 게엠베하 고체 투여 형태를 제조하는 방법 및 윤활제
US20230330169A1 (en) * 2019-12-23 2023-10-19 Prota Therapeutics Pty Ltd Pharmaceutical compositions
WO2022150605A1 (en) 2021-01-08 2022-07-14 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
WO2023198674A1 (en) 2022-04-11 2023-10-19 Alk-Abelló A/S Peanut allergen composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809767A (en) * 1969-05-12 1974-05-07 Griffith Laboratories Methods of making vegetable protein concentrates
AU1589492A (en) 1991-03-01 1992-10-06 Warner-Lambert Company Starch-based controlled release compositions
US20120164306A1 (en) * 1993-08-03 2012-06-28 Girsh Leonard S Process for preparing hypoallergenic and reduced fat foods
JP3445593B2 (ja) * 1994-09-10 2003-09-08 株式会社林原生物化学研究所 ペプチドとその用途
AU1951201A (en) 1999-12-06 2001-06-12 Mount Sinai School Of Medicine Of The City University Of New York, The Peptide antigens
EP1272213B1 (en) * 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
AU2004216559B2 (en) 2003-02-28 2010-05-27 Alk-Abello A/S Dosage form having a saccharide matrix
US7820175B2 (en) 2004-03-19 2010-10-26 Herbal Spring, Llc Herbal therapy for the treatment of food allergy
JP2009522258A (ja) * 2005-12-28 2009-06-11 テバ ファーマシューティカル インダストリーズ リミティド 増大したバイオアベイラビリティを有するフェノフィブラートの医薬製剤
FR2924349B1 (fr) * 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
SG171752A1 (en) 2008-11-19 2011-07-28 Avantor Performance Mat Inc Directly compressible granular microcrystalline cellulose based excipient, manufacturing process and use thereof
CN102159201A (zh) 2008-12-19 2011-08-17 莫茨药物股份两合公司 用于治疗肥大细胞介导的疾病的1-氨基-烷基环己烷衍生物
US8329208B2 (en) * 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
EP2364690A1 (en) 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
JP5800527B2 (ja) * 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
UY33472A (es) * 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
CN101912364B (zh) * 2010-08-09 2015-07-15 刘会梅 银杏内酯b脂质体组合药物
GB201104537D0 (en) 2011-03-17 2011-05-04 Cambridge Entpr Ltd Treatment for peanut allergy
ES2936312T3 (es) * 2011-08-31 2023-03-16 Perosphere Tech Inc Métodos para la desensibilización eficaz y rápida de pacientes alérgicos
WO2013087119A1 (en) 2011-12-16 2013-06-20 Hal Allergy Holding B.V. Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
EP3482771B1 (en) 2013-03-14 2023-01-18 Société des Produits Nestlé S.A. Manufacture of peanut formulations for oral desensitization
WO2016033094A1 (en) 2014-08-25 2016-03-03 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof
SG10201913846XA (en) 2017-01-13 2020-03-30 Aimmune Therapeutics Inc Methods of manufacture of nut flours and formulations for oral immunotherapy
MX2020004683A (es) 2017-11-02 2020-08-13 Aimmune Therapeutics Inc Metodos de inmunoterapia oral.

Also Published As

Publication number Publication date
JP2021073321A (ja) 2021-05-13
EP3482771A1 (en) 2019-05-15
FR23C1026I1 (fr) 2023-10-06
US20160030289A1 (en) 2016-02-04
BR112015021756B1 (pt) 2023-01-10
ES2940686T3 (es) 2023-05-10
US11141352B2 (en) 2021-10-12
BR112015021756A2 (pt) 2017-07-18
PL2968529T3 (pl) 2021-04-19
CA2903229A1 (en) 2014-10-02
US20200129378A1 (en) 2020-04-30
AU2020202685A1 (en) 2020-05-14
EP2968529A1 (en) 2016-01-20
EP2968529B1 (en) 2020-08-05
AU2022201858A1 (en) 2022-04-07
HUE051831T2 (hu) 2021-03-29
US10449118B2 (en) 2019-10-22
US9198869B2 (en) 2015-12-01
PT2968529T (pt) 2020-11-10
DK3482771T3 (da) 2023-03-20
MX2015010315A (es) 2016-04-13
AU2020202685B2 (en) 2022-01-20
US20180042816A1 (en) 2018-02-15
JP2019108357A (ja) 2019-07-04
SI2968529T1 (sl) 2021-03-31
AU2016231523B2 (en) 2018-05-31
EP3482771B1 (en) 2023-01-18
HK1217660A1 (zh) 2017-01-20
AU2022201858B2 (en) 2024-04-04
JP6891205B2 (ja) 2021-06-18
US20230120350A1 (en) 2023-04-20
JP6752140B2 (ja) 2020-09-09
ES2826224T3 (es) 2021-05-17
CN109125283A (zh) 2019-01-04
EP2968529A4 (en) 2016-10-05
CN105101994A (zh) 2015-11-25
EP3998080A1 (en) 2022-05-18
FI3482771T3 (fi) 2023-04-03
AU2016231523A1 (en) 2016-10-06
JP7454519B2 (ja) 2024-03-22
JP2016512537A (ja) 2016-04-28
CN105101994B (zh) 2018-10-12
BR112015021756A8 (pt) 2019-11-19
US20140271836A1 (en) 2014-09-18
AU2014240404A1 (en) 2015-09-17
FIC20230022I1 (fi) 2023-07-04
AU2018222980A1 (en) 2018-09-20
WO2014159607A1 (en) 2014-10-02
AU2014240404B2 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
DK2968529T3 (da) Fremstilling af jordnøddeformuleringer til oral desensibilisering
DK3725778T3 (da) Formuleringer af enzalutamid
DK2845905T3 (da) Fremstilling af oligosaccharider
ES2969363T3 (es) Formulaciones
DK3611262T3 (da) Fremgangsmåder til sekvensering af immunrepertoire
DK3157508T3 (da) Fast oral doseringsform af lipofile forbindelser
DK3049441T3 (da) Anti-PDL1-antistofformuleringer
DK2968071T3 (da) Enhed til oral levering af terapeutiske forbindelser
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
DK3454346T3 (da) Anordning til cylotronfremstilling af technetium-99m
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK2961766T3 (da) Kvantificering af vaccinesammensætninger
DK3185853T3 (da) Inhalerbare pulverformuleringer af alginatoligomerer
DK2961388T3 (da) Kombinationer af lægemidler
DK2968221T3 (da) Farmaceutisk sammensætning af s-ketaminhydrochlorid
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3079669T3 (da) Sammensætninger med forsinket frigivelse af linaclotid
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK3106150T3 (da) Forbedrede farmaceutiske sammensætninger af pimobendan
DK2968214T3 (da) Hidtil ukendte analgetiske sammensætninger
IL245855B (en) Oral formulations of pyrrolidine derivatives
DK3300015T3 (da) System til fremstilling af individuelle formuleringer til individer
DK2931313T3 (da) Opløsningsformuleringer af manipulerede anti-il-23p19-antistoffer
DK2925338T3 (da) Frysetørret formulering af tat-nr2b9c
DK2956149T3 (da) Farmaceutiske sammensætninger til behandling af helicobacter pylori